ANT-GROUP
20.12.2021 05:32:15 CET | Business Wire | Press release
Restaurant Brands International Inc. ("RBI"), one of the world's largest quick service restaurant companies and the owner of TIM HORTONS® , BURGER KING® , and POPEYES® brands, today announced a regional partnership to leverage Ant Group’s digital solutions to accelerate digital transformation of its restaurant operations across Asia Pacific. This deal further complements RBI’s continuous efforts to support local franchisee operations and expansion in the Asia Pacific market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211219005104/en/
Under the collaboration, Ant Group will work with RBI’s local franchisees to implement a range of digital solutions, including mini program Software-as-a-Service (SaaS) solution and Alipay+, a suite of global cross-border mobile payments and marketing solutions. The collaboration aims to enable a more convenient and seamless omni-channel experience for local diners and to uplift the restaurants’ operational efficiency.
With the mini program SaaS solution, Ant Group will develop mini programs for each of RBI’s brands, namely Tim Hortons, Burger King, and Popeyes, adapted for each local market. Via the mini program, RBI’s local franchisees will be able to digitally integrate online and offline operations to drive increased efficiency and gain deeper operational insights. At the same time, diners will have access to expanded services, such as contactless menus and payments, online ordering for pickup or delivery, scan-and-order function in store, etc. Furthermore, the mini programs will also incorporate each RBI brand’s existing loyalty program and provide additional digital marketing capabilities, such as distribution of digital vouchers, etc.
To help RBI’s local restaurants to reach more local diners, the mini programs will be integrated into other local and regional digital platforms, including leading regional F&B tech startup Chope, and e-wallets in Southeast Asia, etc.
The collaboration will also see RBI leveraging the Alipay+ solutions to allow more payment options to be accepted in-store, on websites, apps, and via the mini programs. With the integration of Alipay+ solutions, RBI’s operations will support payment options such as Touch ‘n Go eWallet in Malaysia, True Money wallet in Thailand, GCash in the Philippines, Kakao Pay in South Korea, and many others.
“We couldn’t be more excited to launch this groundbreaking partnership with Ant Group, which further supports our mission to make ordering and dining as easy as possible for our guests and leveraging payments to provide a more convenient and personalized experience,” said Ekrem Ozer, President of APAC, Restaurant Brands International. “Franchisees across Asia will soon be able to benefit from the advantages of digitization across operations and the mini programs’ integration into other digital platforms.”
"Leveraging digital payments and marketing innovations is critical for industries like food and beverage to provide contactless services, boost operational efficiency, and adapt to the fast-changing market conditions,” said Angel Zhao, President of Ant Group’s International Business Group. “We look forward to assisting RBI in its overall digital transformation journey as it reinvents how diners connect with RBI brands both online and offline to create superior customer experiences.”
This activation will take place across eight selected markets in Asia Pacific, and 1,500 restaurants across all three RBI brands.
About Restaurant Brands International Inc.
Restaurant Brands International Inc. is one of the world's largest quick service restaurant companies with approximately $34 billion in annual system-wide sales and over 27,000 restaurants in more than 100 countries. RBI owns three of the world's most prominent and iconic quick service restaurant brands – TIM HORTONS®, BURGER KING®, and POPEYES®. These independently operated brands have been serving their respective guests, franchisees and communities for over 45 years.
About Ant Group
Ant Group aims to create the infrastructure and platform to support the digital transformation of the service industry. It strives to enable all consumers and small and micro businesses to have equal access to financial and other services that are inclusive, green and sustainable.
Ant Group is the owner and operator of Alipay, the leading digital payment platform in China serving hundreds of millions of users, and connecting them with merchants and partner financial institutions that offer inclusive financial services and digital daily life services such as food delivery, transport, entertainment, and healthcare.
Ant Group has further introduced Alipay+, which provides global cross-border mobile payments and marketing solutions that enable global e-wallets and merchant partners, especially small and medium-sized businesses, to better serve their users and customers from all over the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211219005104/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom